Conjugated Polymers-Based Thermal-Responsive Nanoparticles for Controlled Drug Delivery, Tracking, and Synergistic Photodynamic Therapy/Chemotherapy

2019 ◽  
Vol 2 (10) ◽  
pp. 4485-4492 ◽  
Author(s):  
Zhuanning Lu ◽  
Ziqi Zhang ◽  
Yanli Tang
Keyword(s):  
Drug Delivery ◽  
Photodynamic Therapy ◽  
Conjugated Polymers ◽  
Controlled Drug Delivery

Innovative Drug Delivery Strategies for Topical Photodynamic Therapy using Porphyrin Precursors

2007 ◽  
Vol 26 (2) ◽  
pp. 105-116 ◽  
Author(s):  
Desmond I. J. Morrow ◽  
Martin J. Garland ◽  
Paul A. McCarron ◽  
A. David Woolfson ◽  
Ryan F. Donnelly
Keyword(s):  
Drug Delivery ◽  
Photodynamic Therapy ◽  
Innovative Drug ◽  
Delivery Strategies

Optical Properties of Photodynamic Therapy Drugs in Different Environments: The Paradigmatic Case of Temoporfin

2020 ◽  
Author(s):  
busenur Aslanoglu ◽  
Ilya Yakavets ◽  
Vladimir Zorin ◽  
Henri-Pierre Lassalle ◽  
Francesca Ingrosso ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Optical Properties ◽  
Photodynamic Therapy ◽  
Minimally Invasive ◽  
Visible Light ◽  
Cancer Treatment ◽  
Singlet Oxygen ◽  
Tumor Cells ◽  
Molecular Oxygen ◽  
Computational Tools

Computational tools have been used to study the photophysical and photochemical features of photosensitizers in photodynamic therapy (PDT) –a minimally invasive, less aggressive alternative for cancer treatment. PDT is mainly based by the activation of molecular oxygen through the action of a photoexcited sensitizer (photosensitizer). Temoporfin, widely known as mTHPC, is a second-generation photosensitizer, which produces the cytotoxic singlet oxygen when irradiated with visible light and hence destroys tumor cells. However, the bioavailability of the mostly hydrophobic photosensitizer, and hence its incorporation into the cells, is fundamental to achieve the desired effect on malignant tissues by PDT. In this study, we focus on the optical properties of the temoporfin chromophore in different environments –in <i>vacuo</i>, in solution, encapsulated in drug delivery agents, namely cyclodextrin, and interacting with a lipid bilayer.

Atherosclerosis and Nanomedicine Potential: Current Advances and Future Opportunities

2020 ◽  
Vol 27 (21) ◽  
pp. 3534-3554 ◽  
Author(s):  
Fan Jiang ◽  
Yunqi Zhu ◽  
Changyang Gong ◽  
Xin Wei
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Controlled Drug Delivery ◽  
Vascular Wall ◽  
Arterial Disease ◽  
Diagnosis And Treatment ◽  
Antiinflammatory Therapy ◽  
Limited Efficacy ◽  
Conventional Drug ◽  
Diagnostic Modalities

Atherosclerosis is the leading inducement of cardiovascular diseases, which ranks the first cause of global deaths. It is an arterial disease associated with dyslipidemia and changes in the composition of the vascular wall. Besides invasive surgical strategy, the current conservative clinical treatment for atherosclerosis falls into two categories, lipid regulating-based therapy and antiinflammatory therapy. However, the existing strategies based on conventional drug delivery systems have shown limited efficacy against disease development and plenty of side effects. Nanomedicine has great potential in the development of targeted therapy, controlled drug delivery and release, the design of novel specific drugs and diagnostic modalities, and biocompatible scaffolds with multifunctional characteristics, which has led to an evolution in the diagnosis and treatment of atherosclerosis. This paper will focus on the latest nanomedicine strategies for atherosclerosis diagnosis and treatment as well as discussing the potential therapeutic targets during atherosclerosis progress, which could form the basis of development of novel nanoplatform against atherosclerosis.

Sign in / Sign up

Export Citation Format

Share Document